Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.44 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.43 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.43 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.43 |
| ▸ | RRM1 | P23921 | 1/20 | 0.42 |
| ▸ | NOD1 | Q9Y239 | 3/20 | 0.41 |
| ▸ | TLR2 | O60603 | 10/20 | 0.41 |
| ▸ | DGKA | P23743 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28014929 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL27820406 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL27820410 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL11052070 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL3283700 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL539143 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2671379 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL5183216 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL3285881 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 | |
| SCHEMBL2905315 | 1.00 | DPP7 (0.44) | DPP7GNAI3GNAO1GNAI1RRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260000620-A1 | ORAL DOSAGE FORMS | AMRYT ENDO INC (US) | 2026-01-01 | — | — | US | disclosed |
| EP-3861986-B1 | PHARMACEUTICAL COMPOSITIONS COMPRISING POLYPEPTIDES AND RELATED METHODS OF DELIVERY | AMRYT ENDO INC (US) | 2025-11-26 | — | — | EP | disclosed |
| US-20250345438-A1 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | AMRYT ENDO INC (US) | 2025-11-13 | — | — | US | disclosed |
| EP-4516803-A2 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | Amryt Endo, Inc. (US) | 2025-03-05 | — | — | EP | disclosed |
| EP-3528828-B1 | TERLIPRESSIN COMPOSITION FOR USE IN TREATING ASCITES | AMRYT ENDO INC (US) | 2025-01-29 | — | — | EP | disclosed |
| US-20250000933-A1 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | AMRYT PHARMACEUTICALS INC. | 2025-01-02 | — | — | US | disclosed |
| EP-4463141-A1 | ORAL DOSAGE FORMS | Amryt Endo, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| US-11986529-B2 | Pharmaceutical compositions and related methods of delivery | AMRYT ENDO, INC. (US) | 2024-05-21 | — | — | US | disclosed |
| US-11969471-B2 | Pharmaceutical compositions and related methods of delivery | AMRYT ENDO, INC. (US) | 2024-04-30 | — | — | US | disclosed |
| WO-2023137428-A1 | ORAL DOSAGE FORMS | AMRYT ENDO, INC. (US) | 2023-07-20 | — | — | WO | disclosed |
| WO-2012097155-A1 | IMPROVED PHARMACEUTICAL COMPOSITIONS FOR DELIVERY OF FERRIC IRON COMPOUNDS, AND METHODS OF USE THEREOF | CHIASMA INC. (US) | 2012-07-19 | — | — | WO | disclosed |
| US-20120093886-A1 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | AMRYT PHARMACEUTICALS INC. | 2012-04-19 | — | — | US | disclosed |
| US-20120009229-A1 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | AMRYT PHARMACEUTICALS INC. | 2012-01-12 | — | — | US | disclosed |
| US-20110311621-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELVERY | CHIASMA, INC. | 2011-12-22 | — | — | US | disclosed |
| US-20110257095-A1 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | AMRYT ENDO, INC. | 2011-10-20 | — | — | US | disclosed |
| WO-2011116139-A2 | IMPROVED PHARMACEUTICAL COMPOSITIONS AND METHODS OF DELIVERY | CHIASMA INC. (US) | 2011-09-22 | — | — | WO | disclosed |
| WO-2011116115-A1 | ALISKIREN COMPOSITION COMPRISING A MEDIUM CHAIN FATTY ACID, THEIR PROCESS OF MANUFACTURING | NOVARTIS AG (CH) | 2011-09-22 | — | — | WO | disclosed |
| EP-2343982-A2 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | Chiasma Inc. (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20100105627-A1 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | AMRYT ENDO, INC. | 2010-04-29 | — | — | US | disclosed |
| WO-2010032140-A2 | PHARMACEUTICAL COMPOSITIONS AND RELATED METHODS OF DELIVERY | CHIASMA INC. (US) | 2010-03-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260000620-A1 | ORAL DOSAGE FORMS | PCTP, TAS2R13, MLEC | DPP7 3900/4885GNAI3 4401/4885GNAO1 4427/4885 |
| US-20250000933-A1 | TERLIPRESSIN COMPOSITIONS AND THEIR METHODS OF USE | PNLIP, LIPC, LIPA | DPP7 667/4885GNAI3 1214/4885GNAO1 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.